WHAT RESEARCHERS STUDY
Primary research interest.
- Cardiolipin and inner-membrane structure
- Mitochondrial respiration
- Oxidative-stress models
- Barth-syndrome muscle-strength outcomes
NEW
MITOCHONDRIAL RESEARCH · IP-SS31-10
SS-31 / Elamipretide
Mitochondrial membrane and cardiolipin research.
EVIDENCE SNAPSHOT · Approved drug molecule for Barth syndrome
SS-31, also called elamipretide, is a mitochondria-targeting tetrapeptide that binds cardiolipin. In 2025 the FDA granted accelerated approval to the prescription product Forzinity for improving muscle strength in patients with Barth syndrome weighing at least 30 kg.
10 mg / vial$110.00 CAD
FOR LABORATORY RESEARCH USE ONLYNot for human or animal consumption. No dosing or administration information is provided.
COMMUNITY DISCUSSION · ANECDOTAL
What people discuss online.
Reddit communities often discuss SS-31 in relation to fatigue, cellular energy and mitochondrial dysfunction. Experiences range from perceived energy improvement to worsened fatigue.
Community reports can be affected by placebo effects, concurrent products, training, diet, selection bias and inaccurate product identity.
EVIDENCE LIMITS
What the page does not claim.
FDA approval is limited to a specific prescription product and a narrow rare-disease indication. It does not validate unapproved research material or broad anti-ageing claims.
SOURCES & FURTHER READING
Review the evidence directly.
FDA accelerated approval announcement ↗Elamipretide research review — PubMed ↗Community discussion — Reddit ↗Related catalog materials
View full catalog →
